Nektar Therapeutics Aktie
WKN: 165417 / ISIN: US6402681083
04.01.2023 15:00:00
|
Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA
SAN FRANCISCO, Jan. 4, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2023 at 8:15 a.m. Pacific Time. The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. This webcast will be available for replay until February 11, 2023.
About Nektar
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology and immunology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama. Further information about the company and its drug development programs and capabilities may be found online at https://www.nektar.com.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-president-and-ceo-howard-robin-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-in-san-francisco-ca-301713076.html
SOURCE Nektar Therapeutics

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nektar Therapeuticsmehr Nachrichten
12.05.25 |
Zuversicht in New York: NASDAQ Composite legt zum Handelsende deutlich zu (finanzen.at) | |
12.05.25 |
Optimismus in New York: Das macht der NASDAQ Composite am Nachmittag (finanzen.at) | |
12.05.25 |
Montagshandel in New York: NASDAQ Composite klettert mittags deutlich (finanzen.at) | |
12.05.25 |
Handel in New York: NASDAQ Composite zum Start auf Höhenflug (finanzen.at) | |
09.05.25 |
NASDAQ Composite Index-Wert Nektar Therapeutics-Aktie: So viel Verlust hätte ein Investment in Nektar Therapeutics von vor 5 Jahren eingebracht (finanzen.at) | |
07.05.25 |
Ausblick: Nektar Therapeutics legt Quartalsergebnis vor (finanzen.net) | |
05.05.25 |
Börse New York: NASDAQ Composite schwächelt zum Ende des Montagshandels (finanzen.at) | |
05.05.25 |
Schwacher Wochentag in New York: NASDAQ Composite verbucht am Nachmittag Abschläge (finanzen.at) |
Analysen zu Nektar Therapeuticsmehr Analysen
Aktien in diesem Artikel
Nektar Therapeutics | 0,64 | 25,02% |
|